48,466
edits
Difference between revisions of "Hepatocyte nuclear factor-1beta"
Jump to navigation
Jump to search
Hepatocyte nuclear factor-1beta (view source)
Revision as of 17:29, 5 August 2021
, 17:29, 5 August 2021no edit summary
| (12 intermediate revisions by the same user not shown) | |||
| Line 3: | Line 3: | ||
==Positive== | ==Positive== | ||
*[[Clear cell carcinoma of the ovary]]. | *[[Clear cell carcinoma of the ovary]]. | ||
*[[ | *[[Renal cell carcinoma]]s - including [[clear cell renal cell carcinoma]].<ref name=pmid26574638>{{cite journal |authors=Hanley KZ, Cohen C, Osunkoya AO |title=Hepatocyte Nuclear Factor-1β Expression in Clear Cell Renal Cell Carcinoma and Urothelial Carcinoma With Clear Cell Features: A Potential Diagnostic Pitfall |journal=Appl. Immunohistochem. Mol. Morphol. |volume=25 |issue=2 |pages=134–138 |date=February 2017 |pmid=26574638 |doi=10.1097/PAI.0000000000000279 |url=}}</ref><ref name=pmid32150988>{{cite journal |authors=Kim M, Joo JW, Lee SJ, Cho YA, Park CK, Cho NH |title=Comprehensive Immunoprofiles of Renal Cell Carcinoma Subtypes |journal=Cancers (Basel) |volume=12 |issue=3 |pages= |date=March 2020 |pmid=32150988 |pmc=7139472 |doi=10.3390/cancers12030602 |url=}}</ref> | ||
*[[Pancreatic ductal adenocarcinoma]] and other [[foregut primary carcinomas]].<ref name=pmid30065837>{{cite journal |authors=Yang MX, Coates RF, Ambaye A, Gardner JA, Zubarick R, Gao Y, Skelly J, Liu JG, Mino-Kenudson M |title=Investigation of HNF-1B as a diagnostic biomarker for pancreatic ductal adenocarcinoma |journal=Biomark Res |volume=6 |issue= |pages=25 |date=2018 |pmid=30065837 |pmc=6062876 |doi=10.1186/s40364-018-0139-6 |url=}}</ref> | |||
Note: | Note: | ||
*CA-125, RCCma, and CD10 can help distinguish | *CA-125, RCCma, and CD10 can help distinguish ''clear cell renal cell carcinoma'' and ''Müllerian clear cell tumours''.<ref name=pmid25279712>{{cite journal |authors=Mentrikoski MJ, Wendroth SM, Wick MR |title=Immunohistochemical distinction of renal cell carcinoma from other carcinomas with clear-cell histomorphology: utility of CD10 and CA-125 in addition to PAX-2, PAX-8, RCCma, and adipophilin |journal=Appl Immunohistochem Mol Morphol |volume=22 |issue=9 |pages=635–41 |date=October 2014 |pmid=25279712 |doi=10.1097/PAI.0000000000000004 |url=}}</ref> | ||
===Occasionally positive=== | |||
*[[Lung adenocarcinoma]].<ref name=pmid30065837/> | |||
*[[Prostate adenocarcinoma]].<ref name=pmid30065837/> | |||
*Gastroesophageal adenocarcinoma.<ref name=pmid30065837/> | |||
==Negative== | ==Negative== | ||
*[[Serous carcinoma of the ovary]]. | *[[Serous carcinoma of the ovary]]. | ||
*[[Hepatocellular carcinoma]].<ref name=pmid30065837/> | |||
*[[Colorectal adenocarcinoma]].<ref name=pmid30065837/> | |||
*[[Breast adenocarcinoma]].<ref name=pmid30065837/> | |||
*[[Lung squamous cell carcinoma]].<ref name=pmid30065837/> | |||
==References== | ==References== | ||
{{Reflist| | {{Reflist|2}} | ||
[[Category:Immunohistochemistry]] | [[Category:Immunohistochemistry]] | ||